Investigators developed a specific aptamer against EpCAM and tested its potential as a drug delivery agent for hepatocellular carcinoma.
[Journal of Controlled Release]
Sorry, but the selected Zotpress account can't be found.
Home Newsletters Cancer Stem Cell News Aptamer-Mediated Doxorubicin Delivery Reduces HCC Burden in 3D Organoids Model
